Department of Pediatric Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
J Cancer Res Ther. 2024 Aug 1;20(4):1195-1200. doi: 10.4103/jcrt.jcrt_1950_23. Epub 2024 Aug 29.
Elevated plasma D-dimer levels are an unfavorable prognostic indicator for various tumors. However, its predictive value for prognosis in pediatric patients with Wilms tumor (WT) remains unknown. We aimed to investigate the clinical and prognostic value of preoperative plasma D-dimer levels and other clinicopathological characteristics in patients with favorable histology WT (FHWT).
The clinical data of 74 children with FHWT from January 2010 to January 2022 were retrospectively analyzed. The clinicopathologic characteristics, preoperative laboratory parameter results, including D-dimer level, and follow-up data were collected. Based on the postoperative recovery status, the patients were divided into tumor-free survival and disease progression groups. The risk factors affecting disease progression in pediatric patients with WT and the impact of plasma D-dimer levels on overall survival (OS) were evaluated.
Over a median follow-up of 33 months (range: 2-145 months), 56 patients survived without progression. Relapses and metastases occurred in 18 patients, of which four survived and 14 died. Higher preoperative plasma D-dimer levels (>0.865) (Odds ratio [OR] = 7.240, 95% confidence interval (CI) = 1.276-33.272, P = 0.011) and tumor rupture (OR = 19.984, 95% CI = 1.182-338.013, P = 0.038) were independent prognostic factors for disease progression. Additionally, patients with elevated D-dimer levels demonstrated a worse 5-year OS than those with low D-dimer levels (Hazard ratio (HR) =4.278, 95% CI = 1.074-17.035, P = 0.039).
Elevated D-dimer levels are a prognostic factor for a poorer outcome in pediatric patients with WT and are expected to become a clinical biomarker for predicting the prognosis of WT.
血浆 D-二聚体水平升高是多种肿瘤的预后不良指标。然而,其在儿童肾母细胞瘤(WT)患者中的预后预测价值尚不清楚。我们旨在研究术前血浆 D-二聚体水平和其他临床病理特征在具有良好组织学特征的 WT(FHWT)患者中的临床和预后价值。
回顾性分析 2010 年 1 月至 2022 年 1 月间 74 例 FHWT 患儿的临床资料。收集患儿的临床病理特征、术前实验室参数结果(包括 D-二聚体水平)和随访资料。根据术后恢复情况,将患儿分为无肿瘤生存组和疾病进展组。评估影响 WT 患儿疾病进展的危险因素,以及血浆 D-二聚体水平对总生存(OS)的影响。
中位随访 33 个月(范围:2-145 个月),56 例患儿无进展生存。18 例患儿复发转移,其中 4 例存活,14 例死亡。术前较高的血浆 D-二聚体水平(>0.865)(优势比[OR] = 7.240,95%置信区间[CI] = 1.276-33.272,P = 0.011)和肿瘤破裂(OR = 19.984,95%CI = 1.182-338.013,P = 0.038)是疾病进展的独立预后因素。此外,D-二聚体水平升高的患儿 5 年 OS 较 D-二聚体水平较低的患儿更差(风险比[HR] = 4.278,95%CI = 1.074-17.035,P = 0.039)。
D-二聚体水平升高是儿童 WT 患者预后不良的一个预后因素,有望成为预测 WT 预后的临床生物标志物。